Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

ClinicalTrials.gov ID: NCT00362466

Public ClinicalTrials.gov record NCT00362466. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Randomized Phase III Study of Dasatinib vs. High-Dose (600 mg) Imatinib Mesylate in the Treatment of Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Are Imatinib Failures or Who Have Had a Suboptimal Response After 3-18 Months of Therapy With 400 mg Imatinib

Study identification

NCT ID
NCT00362466
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
3 participants

Conditions and interventions

Conditions

Interventions

  • Dasatinib Drug
  • Imatinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2007
Primary completion
May 31, 2008
Completion
May 31, 2008
Last update posted
Nov 19, 2009

2007 – 2008

United States locations

U.S. sites
45
U.S. states
22
U.S. cities
42
Facility City State ZIP Site status
Dr. Marshall Schreeder Huntsville Alabama 35805
Local Institution Little Rock Arkansas 72205
Local Institution Alhambra California 91801
Local Institution Anaheim California 92801
Local Institution Beverly Hills California 90211
Local Institution Fullerton California 92835
Local Institution La Jolla California 92093
Local Institution La Verne California 91750
Local Institution Long Beach California 90813
Local Institution Los Angeles California 90033
Local Institution Los Angeles California 90048
Local Institution Los Angeles California 90095
Local Institution Northridge California 91325
Local Institution Oxnard California 93030
Local Institution Redondo Beach California 90277
Local Institution San Francisco California 94143
Local Institution Santa Maria California 93454
Local Institution Stanford California 94305
Local Institution Aurora Colorado 80045
Local Institution Jacksonville Florida 32207
Local Institution Jacksonville Florida 32209
M.D. Anderson Cancer Center Orlando Orlando Florida 32806
Local Institution Pembroke Pines Florida 33028
Local Institution Chicago Illinois 60637
Local Institution Indianapolis Indiana 46202
Local Institution Kansas City Kansas 66160
Local Institution Hazard Kentucky 41701
Local Institution Ann Arbor Michigan 48109
Local Institution Rochester Minnesota 55905
Local Institution St Louis Missouri 63110
Local Institution Omaha Nebraska 68114
Local Institution Las Vegas Nevada 89135
Local Institution Hackensack New Jersey 07601
Local Institution Buffalo New York 14263
New York Presbyterian Hospital New York New York 10021
New York Medical College Valhalla New York 10595
Local Institution Durham North Carolina 27710
Local Institution Cleveland Ohio 44195
Local Institution Oklahoma City Oklahoma 73112
Local Institution Tulsa Oklahoma 74136
Local Institution Baltimore Pennsylvania 21229
Local Institution Pittsburgh Pennsylvania 15232
Santee Hematology/Oncology Sumter South Carolina 29150
Local Institution Dallas Texas 75390
Local Institution Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00362466, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2009 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00362466 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →